Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

Summary

The main purpose of this study is to determine whether deferoxamine and xingnaojing injection is effective and safe as a treatment for intracerebral hemorrhage.

Conditions

• Intracerebral Hemorrhage

Interventions

DRUG

deferoxamine

Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.

DRUG

Xingnaojing injection

Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.

DRUG

Normal saline

This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.

Sponsors & Collaborators

• Beijing Tiantan Hospital

  collaborator OTHER

• Peking University First Hospital

  collaborator OTHER

• People's Hospital of Beijing Daxing District

  collaborator OTHER

• Beijing Haidian Hospital

  collaborator OTHER

• The 263 Hospital of PLA

  collaborator UNKNOWN

• Beijing Aerospace General Hospital

  collaborator OTHER

• Peking University Third Hospital

  collaborator OTHER

• Beijing Pinggu District Hospital

  collaborator OTHER

• Beijing Shuyi Hospital

  collaborator OTHER

• General Hospital of Beijing PLA Military Region

  collaborator OTHER

• Beijing Luhe Hospital

  collaborator OTHER

• Beijing Fangshan District Liangxiang Hospital

  collaborator OTHER

• Beijing Neurosurgical Institute

  collaborator OTHER

• Beijing Jishuitan Hospital

  collaborator OTHER

• Beijing Ditan Hospital

  collaborator OTHER

• Beijing Youyi Hospital

  collaborator UNKNOWN

• Xiyuan Hospital of China Academy of Chinese Medical Sciences

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• The Second Artillery General Hospital

  collaborator OTHER

• Chinese PLA General Hospital

  collaborator OTHER

• Capital Medical University

  lead OTHER

Principal Investigators

• Maolin He, MD · Department of Neurology，Beijing Shijitan Hospital，Capital Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-03-31

Primary Completion

2016-12-31

Completion

2016-12-31

Countries

• China

Study Locations